Skip to main
TVRD

TVRD Stock Forecast & Price Target

TVRD Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 17%
Sell 17%
Strong Sell 0%

Bulls say

Tvardi Therapeutics is driven by their innovative approach to developing oral, small molecules that target STAT3, a key protein in inflammatory and fibrotic diseases. With promising results from their Phase 1 trials for liver cancer and ongoing studies for other diseases, the company has potential to make a significant impact in the biopharmaceutical industry. However, it is important to closely monitor the progress of their clinical trials as any delays or setbacks could greatly affect the company's future success.

Bears say

Tvardi Therapeutics is a clinical-stage biopharmaceutical company with a negative outlook due to recent setbacks in their clinical trials. The company's lead program, TTI-101, is currently in Phase 2 clinical development for hepatocellular carcinoma (HCC), but topline results are not expected until 2H26. In addition, the company encountered a meaningful clinical setback when their Phase 2 REVERT trial for idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint in October 2025. Although the company has a potentially promising next-generation compound, TTI-109, in development, it is currently undervalued as TTI-101 remains the primary value driver in their pipeline. The company also faces competition from existing therapies and has experienced high gastrointestinal (GI) discontinuation rates in their trials, which could hinder their success in the market.

TVRD has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cara Therapeutics Inc (TVRD) Forecast

Analysts have given TVRD a Buy based on their latest research and market trends.

According to 6 analysts, TVRD has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cara Therapeutics Inc (TVRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.